Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader
To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contri